The DOI matches its Crossref record; 529 of the 529 references it cites were found in a registry or an index.
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance
Abstract
These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry Guidelines for Biological Treatment of Schizophrenia published in 2005. For this 2012 revision, all available publications pertaining to the biological treatment of schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations that are clinically and scientifically meaningful and these guidelines are intended to be used by all physicians diagnosing and treating people suffering from schizophrenia. Based on the first version of these guidelines, a systematic review of the MEDLINE/PUBMED database and the Cochrane Library, in addition to data extraction from national treatment guidelines, has been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into six levels of evidence (A-F; Bandelow et al. 2008b, World J Biol Psychiatry 9:242). This first part of the updated guidelines covers the general descriptions of antipsychotics and their side effects, the biological treatment of acute schizophrenia and the management of treatment-resistant schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–400 of 529
Wu, R., Zhao, J., Liu, Z., Zhai, J., Guo, X., Guo, W., & Tang, J. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0384-5 · Cited by 170
Clozapine's effectiveness for patients in state hospitals: results from a randomized trial.
Essock, S. M., Hargreaves, W. A., Covell, N. H., & Goethe, J. (1996) · PubMed · Cited by 169
Kishimoto, T., Agarwal, V, Kishi, T., Leucht, S., Kane, J. M., & Correll, C. U. (2013) · Molecular Psychiatry · doi:10.1038/mp.2011.143 · Cited by 169
Stroup, T. S., Lieberman, J. A., McEvoy, J. P., Swartz, M. S., Davis, S. M., Capuano, G. A., Rosenheck, R. A., Keefe, R. S. E., Miller, A. L., Belz, I., et al. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.3.415 · Cited by 168
Self-citationPerkins, D. O., Lieberman, J. A., Gu, H., Tohen, M., McEvoy, J., Green, A. I., Zipursky, R. B., Strakowski, S. M., Sharma, T., Kahn, R. S., et al. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.185.1.18 · Cited by 165
Self-citationLeucht, S., Helfer, B., Dold, M., Kissling, W., & McGrath, J. J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003834.pub3 · Cited by 163
Second-generation antipsychotics and constipation: A review of the literature
Hert, M. D., Hudyana, H., Dockx, L., Bernagie, C., Sweers, K., Tack, J. F., Leucht, S., & Peuskens, J. (2010) · European Psychiatry · doi:10.1016/j.eurpsy.2010.03.003 · Cited by 163
for the MEM-MD-29 Study Group, Lieberman, J. A., Papadakis, K., Csernansky, J., Litman, R., Volavka, J., Jia, X. D., & Gage, A. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.200 · Cited by 162 · cited 1×
“One large ( n 138 patients) double-blind, placebo-controlled study compared the adjunctive treatment of either memantine or placebo to the standard SGAs treatment and did not fi nd a signifi cant difference between both groups (Lieberman et al. 2009).”
Harvey, P. D., Rabinowitz, J., Eerdekens, M., & Davidson, M. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.10.1888 · Cited by 161
Neuroleptic-induced hyperprolactinemia
Dickson, R. A., & Glazer, W. M. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00159-5 · Cited by 161
Clozapine: Efficacy and Safety
Buchanan, R. W. (1995) · Schizophrenia Bulletin · doi:10.1093/schbul/21.4.579 · Cited by 161
Haloperidol versus placebo for schizophrenia
Adams, C. E., Bergman, H., Irving, C. B., & Lawrie, S. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003082.pub3 · Cited by 159
Meltzer, H. Y., Bobo, W. V., Nuahmah, I. F., Lane, R., Hough, D., Kramer, M., & Eerdekens, M. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0515 · Cited by 158
Second-generation antipsychotics for schizophrenia: can we resolve the conflict?
Leucht, S., Kissling, W., & Davis, J. M. (2009) · Psychological Medicine · doi:10.1017/s0033291709005455 · Cited by 158
Strategies for Improving Treatment Adherence in Schizophrenia and Schizoaffective Disorder
GOFF, D. C., Hill, M. B., & Freudenreich, O. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.9096su1cc.04 · Cited by 157
A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia
van Kammen, D. P., McEvoy, J. P., Targum, S. D., Kardatzke, D. R., & Sebree, T. B. (1996) · Psychopharmacology · doi:10.1007/bf02245618 · Cited by 157
Woodward, N. D., Purdon, S. E., Meltzer, H. Y., & Zald, D. H. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.08.021 · Cited by 156
Relationship Between Clinical Efficacy and Clozapine Concentrations in Plasma in Schizophrenia
Hasegawa, M., Gutierrez-Esteinou, R., Way, L. E., & Meltzer, H. Y. (1993) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199312000-00003 · Cited by 155
Neuroleptic Malignant Syndrome Associated with Atypical Antipsychotic Drugs
Trollor, J. N., Chen, X., & Sachdev, P. S. (2009) · CNS Drugs · doi:10.2165/00023210-200923060-00003 · Cited by 154
Meyer‐Massetti, C., Cheng, C. M., Sharpe, B. A., Meier, C. R., & Guglielmo, B. J. (2010) · Journal of Hospital Medicine · doi:10.1002/jhm.691 · Cited by 154
Treatment of neuroleptic-resistant schizophrenic relapse.
Kinon, B. J., Kane, J. M., Johns, C. A., Perovich, R., Ismi, M. A., Koreen, A., & Weiden, P. J. (1993) · PubMed · Cited by 154
Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia
Barber, S., Olotu, U., Corsi, M., & Cipriani, A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006324.pub3 · Cited by 153
A 28-Week Comparison of Ziprasidone and Haloperidol in Outpatients With Stable Schizophrenia
Hirsch, S. R., Kissling, W., Bäuml, J., Power, A., & O'Connor, R. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0609 · Cited by 152
Aripiprazole versus other atypical antipsychotics for schizophrenia
Khanna, P., Suo, T., Komossa, K., Ma, H., Rummel-Kluge, C., El-Sayeh, H. G., Leucht, S., & Xia, J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006569.pub5 · Cited by 151
Haloperidol plus promethazine for psychosis-induced aggression
Huf, G., Alexander, J., Gandhi, P., & Allen, M. H. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005146.pub3 · Cited by 151
Lange, J. J. D.-D., Knegtering, R., & Aleman, A. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08r04808yel · Cited by 151
Kane, J. M., Meltzer, H. Y., Carson, W. H., McQuade, R. D., Marcus, R. N., Sanchez, R., & Aripiprazole Study Group (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0206 · Cited by 151
Assessing QT Interval Prolongation and its Associated Risks with Antipsychotics
Nielsen, J., Graff, C., Kanters, J. K., Toft, E. S., Taylor, D. M., & Meyer, J. M. (2011) · CNS Drugs · doi:10.2165/11587800-000000000-00000 · Cited by 149
Risperidone in Treatment-Refractory Schizophrenia
Wirshing, D. A., Marshall, B. D., Green, M. F., Mintz, J., Marder, S. R., & Wirshing, W. C. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.9.1374 · Cited by 148
Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia
Bitter, I., Dossenbach, M. R. K., Brook, S., Feldman, P. D., Metcalfe, S., Gagiano, C. A., Füredi, J., Bartkó, G., Janka, Z., Bánki, C. M., et al. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.033 · Cited by 147
Möller, H., Müller, H., Borison, R. L., Schooler, N. R., & Chouinard, G. (1995) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf02191543 · Cited by 147
Self-citationChrzanowski, W., Marcus, R. N., Torbeyns, A. F., Nyilas, M., & McQuade, R. D. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0564-3 · Cited by 146
Catatonia: Diagnosis, Classification, and Treatment
Francis, A. (2010) · Current Psychiatry Reports · doi:10.1007/s11920-010-0113-y · Cited by 146
The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine
Kern, R. S., Green, M. F., Cornblatt, B. A., Owen, J. R., McQuade, R. D., Carson, W. H., Ali, M. W., & Marcus, R. N. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0428-x · Cited by 145
Copolov, D., Link, C. G. G., & Kowalcyk, B. B. (2000) · Psychological Medicine · doi:10.1017/s0033291799001476 · Cited by 144
Continuation ECT in Treatment-Resistant Schizophrenia
Chanpattana, W., Chakrabhand, M. L. S., Sackeïm, H. A., Kitaroonchai, W., Kongsakon, R., Techakasem, P., Buppanharun, W., Tuntirungsee, Y., & Kirdcharoen, N. (1999) · Journal of Ect · doi:10.1097/00124509-199909000-00002 · Cited by 144
Early Prediction of Antipsychotic Nonresponse Among Patients With Schizophrenia
Leucht, S., Busch, R. M., Kissling, W., & Kane, J. M. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0301 · Cited by 143
Puech, A. J., Fleurot, O., Rein, W., & Amisulpride Study Group (1998) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1998.tb10044.x · Cited by 143
Polyunsaturated fatty acid supplementation for schizophrenia
Irving, C. B., Mumby-Croft, R., & Joy, L. A. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001257.pub2 · Cited by 143
Bieniek, S., Ownby, R. L., Peñalver, A., & Dominguez, R. A. (1998) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1998.tb03827.x · Cited by 142
Paton, C., Barnes, T. R. E., Cavanagh, M.-R., Taylor, D. M., & Lelliott, P. T. (2008) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.107.042895 · Cited by 142
Improvement of some schizophrenic deficit symptoms with low doses of amisulpride
Martinot, M. P., Lecrubier, Y., Martinot, J., & Aubin, F. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.1.130 · Cited by 142
Results of phase 3 of the CATIE schizophrenia trial
Stroup, T. S., Lieberman, J. A., McEvoy, J. P., Thomas, S., Swartz, M. S., Keefe, R. S. E., Miller, A. L., Rosenheck, R. A., & Hsiao, J. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.10.011 · Cited by 141
Self-citationMullen, J., Jibson, M. D., & Sweitzer, D. E. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)89080-3 · Cited by 141
Management of the Negative Symptoms of Schizophrenia: New Treatment Options
M??ller, H.-J. (2003) · CNS Drugs · doi:10.2165/00023210-200317110-00003 · Cited by 141
Self-citationLong-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia
Colonna, L., Saleem, P., Dondey-Nouvel, L., & Rein, W. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200015010-00002 · Cited by 139
Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol
Möller, H. ‐., Boyer, P., Fleurot, O., & Rein, W. (1997) · Psychopharmacology · doi:10.1007/s002130050361 · Cited by 139
Self-citationRevicki, D. A., Genduso, L. A., Hamilton, S. H., Ganoczy, D. A., & Beasley, C. M. (1999) · Quality of Life Research · doi:10.1023/a:1008958925848 · Cited by 137
Baandrup, L., Gasse, C., Jensen, V. D., Glenthoj, B. Y., Nordentoft, M., Lublin, H., Fink‐Jensen, A., Lindhardt, A., & Mortensen, P. B. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04818yel · Cited by 137
Self-citationOlanzapine and haloperidol in first episode psychosis: Two-year data
Green, A. I., Lieberman, J. A., Hamer, R. M., Glick, I. D., Gur, R. C., Kahn, R. S., McEvoy, J. P., Perkins, D. O., Rothschild, A. J., Sharma, T., et al. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.06.021 · Cited by 134
Self-citationde Lucena, D. F., Fernandes, B. S., Berk, M., Dodd, S., Medeiros, D. W., Pedrini, M., Kunz, M., Gomes, F. A., Giglio, L. M. F., Lobato, M. I. R., et al. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04935gry · Cited by 133
Long-Term Neurocognitive Effects of Olanzapine or Low-Dose Haloperidol in First-Episode Psychosis
Keefe, R. S. E., Seidman, L. J., Christensen, B. K., Hamer, R. M., Sharma, T., Sitskoorn, M. M., Rock, S. L., Woolson, S., Tohen, M. F., Tollefson, G. D., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.06.022 · Cited by 131
Self-citationEffectiveness of Switching to Ziprasidone for Stable but Symptomatic Outpatients With Schizophrenia
Weiden, P. J., Simpson, G. M., Potkin, S. G., & O’Sullivan, R. L. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0514 · Cited by 130
Aripiprazole for schizophrenia: Systematic review
El-Sayeh, H. G. G., Morganti, C., & Adams, C. E. (2006) · The British Journal of Psychiatry · doi:10.1192/bjp.189.2.102 · Cited by 130
Wetzel, H., Gründer, G., Hillert, A., Philipp, M., Gattaz, W. F., Sauer, H., Adler, G., Schröder, J., Rein, W., & Benkert, O. (1998) · Psychopharmacology · doi:10.1007/s002130050614 · Cited by 129
Self-citationDepressogenic effects of medications: a review
Celano, C. M., Freudenreich, O., Fernandez-Robles, C. G., Stern, T. A., Caro, M. A., & Huffman, J. C. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.1/ccelano · Cited by 128
Kane, J. M., Meltzer, H. Y., Carson, W. H., et al. (2007) · PubMed · Cited by 128
Lamotrigine as Add-On Therapy in Schizophrenia: Results of 2 Placebo-Controlled Trials
GOFF, D. C., Keefe, R. S. E., Citrome, L., Davy, K., Krystal, J. H., Large, C. H., Thompson, T. R., Volavka, J., & Webster, E. L. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31815abf34 · Cited by 128
Kane, J. M., Correll, C. U., GOFF, D. C., Kirkpatrick, B. W., Marder, S. R., Vester-Blokland, E., Sun, W., Carson, W. H., Pikalov, A., & Assunção-Talbott, S. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05154yel · Cited by 127
Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis
Carman, J. S., Peuskens, J., & Vangeneugden, A. (1995) · International Clinical Psychopharmacology · doi:10.1097/00004850-199511000-00001 · Cited by 127
Kane, J. M., Cohen, M., Zhao, J., Alphs, L., & Panagides, J. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181d35d6b · Cited by 126
Kerwin, R. W., Millet, B., Herman, E., Bánki, C. M., Lublin, H., Pans, M., Hanssens, L., L'Italien, G. J., McQuade, R. D., & Beuzen, J. N. (2007) · European Psychiatry · doi:10.1016/j.eurpsy.2007.03.002 · Cited by 126
Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia
Suzuki, T., Uchida, H., Tanaka, K. F., Nomura, K., Takano, H., Tanabe, A., Watanabe, K., Yagi, G., & Kashima, H. (2004) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703004012 · Cited by 126
Efficacy and Safety of Intramuscular Aripiprazole in Patients With Acute Agitation
Tran-Johnson, T. K., Sack, D. A., Marcus, R. N., et al. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0115 · Cited by 126
Breier, A. F., & Hamilton, S. H. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00291-1 · Cited by 126
Antipsychotic Drugs and QT Interval Prolongation
Zaręba, W., & Lin, D. A. (2003) · Psychiatric Quarterly · doi:10.1023/a:1024122706337 · Cited by 125
Dursun, S. M., & Deakin, J. F. W. (2001) · Journal of Psychopharmacology · doi:10.1177/026988110101500409 · Cited by 124
Andrezina, R., Josiassen, R. C., Marcus, R. N., Oren, D. A., Manos, G., Stock, E. G., Carson, W. H., & Iwamoto, T. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0541-x · Cited by 123
Garza-Treviño, E. S., Hollister, L. E., Overall, J. E., & Alexander, W. F. (1989) · American Journal of Psychiatry · doi:10.1176/ajp.146.12.1598 · Cited by 123
Srisurapanont, M., Maneeton, B., Maneeton, N., Lankappa, S. T., & Gandhi, R. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000967.pub2 · Cited by 122
The Scottish first episode schizophrenia study
McCreadie, R. G., Wiles, D., Grant, S. M., Crocket, G. T., Mahmood, Z., Livingston, M. G., Watt, J. A. G., Greene, J. G., Kershaw, P. W., Todd, N. A., et al. (1989) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1989.tb03032.x · Cited by 120
Amisulpride vs. Risperidone in Chronic Schizophrenia Results of a 6-month Double-blind Study
Sechter, D. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00375-5 · Cited by 120
Foster, S., Kessel, J., Berman, M. E., & Simpson, G. M. (1997) · International Clinical Psychopharmacology · doi:10.1097/00004850-199705000-00009 · Cited by 120
Benzodiazepines for psychosis-induced aggression or agitation
Zaman, H., Sampson, S. J., Beck, A., Sharma, T., Clay, F. J., Spyridi, S., Zhao, S., & Gillies, D. M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003079.pub4 · Cited by 119
Blin, O., Azorin, J. M., & Bouhours, P. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199602000-00007 · Cited by 117
Hamilton, S. H. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00111-5 · Cited by 117
Glutamatergic drugs for schizophrenia
Tiihonen, J., & Wahlbeck, K. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003730.pub2 · Cited by 116
Cutler, A. J., Kalali, A. H., Weiden, P. J., Hamilton, J., & Wolfgang, C. D. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318169d4ce · Cited by 113
Tandon, R., Marcus, R. N., Stock, E. G., Riera, L. C., Kostic, D., Pans, M., McQuade, R. D., Nyilas, M., Iwamoto, T., & CRANDALL, D. T. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2005.12.857 · Cited by 113
Meyer‐Lindenberg, A., Gruppe, H., Bauer, U., Lis, S., Krieger, S., & Gallhofer, B. (1997) · Pharmacopsychiatry · doi:10.1055/s-2007-979481 · Cited by 112
Citrome, L., Casey, D. E., Daniel, D. G., Wozniak, P., Kochan, L. D., & Tracy, K. A. (2004) · Psychiatric Services · doi:10.1176/appi.ps.55.3.290 · Cited by 111
Kee, K. S., Kern, R. S., Marshall, B. D., & Green, M. F. (1998) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00026-7 · Cited by 110
The CATIE and CUtLASS Studies in Schizophrenia: Results and Implications for Clinicians
Naber, D., & Lambert, M. (2009) · CNS Drugs · doi:10.2165/00023210-200923080-00002 · Cited by 109
Robinson, D. G., Woerner, M. G., Napolitano, B. A., Patel, R. C., Sevy, S. M., Gunduz‐Bruce, H., Soto-Perello, J. M., Mendelowitz, A. J., Khadivi, A., Miller, R., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.12.2096 · Cited by 109
Mcloughlin, B. C., Pushpa-Rajah, J. A., Gillies, D. M., Rathbone, J., Variend, H., Kalakouti, E., & Kyprianou, K. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004837.pub3 · Cited by 109
Lindenmayer, J., Khan, A., Iskander, A., Abad, M. T., & Parker, B. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0303 · Cited by 108
Effects of an Alpha 7-Nicotinic Agonist on Default Network Activity in Schizophrenia
Tregellas, J. R., Tanabe, J., Rojas, D. C., Shatti, S., D, A. O. M., Johnson, L. L., Martín, L., Soti, F. S., Kem, W. R., Leonard, S. S., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.07.004 · Cited by 107
Kremer, I., Vass, Á., Gorelik, I., Bar, G., Blanaru, M., Javitt, D. C., & Heresco‐Levy, U. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.06.029 · Cited by 107
McEvoy, J. P., Daniel, D. G., Carson, W. H., McQuade, R. D., & Marcus, R. N. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2007.05.002 · Cited by 106
Freudenreich, O., Henderson, D. C., Walsh, J. P., Maravić, M. C., & GOFF, D. C. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2006.12.030 · Cited by 106
Zoccali, R. A., Muscatello, M. R. A., Bruno, A., Cambria, R., Micò, U., Spina, E., & Meduri, M. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.02.009 · Cited by 106
Berk, M., Ichim, C., & Brook, S. (2001) · International Clinical Psychopharmacology · doi:10.1097/00004850-200103000-00003 · Cited by 104
Ko, Y., Joe, S.-H., Jung, I., & Kim, S. (2005) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000172994.56028.c3 · Cited by 103
Speller, J. C., Barnes, T. R. E., Curson, D. A., Pantelis, C., & Alberts, J. (1997) · The British Journal of Psychiatry · doi:10.1192/bjp.171.6.564 · Cited by 103
Fleischhacker, W. W., McQuade, R. D., Marcus, R. N., Archibald, D., Swanink, R., & Carson, W. H. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.07.033 · Cited by 103
Efficacy of olanzapine: an overview of pivotal clinical trials.
Beasley, C. M., Tollefson, G. D., & Tran, P. V. (1997) · PubMed · Cited by 102
Potkin, S. G., Gharabawi, G. M., Greenspan, A. J., Mahmoud, R. A., Kosik‐Gonzalez, C., Rupnow, M. F. T., Bossie, C. A., Davidson, M., Burtea, V., ZHU, Y., et al. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.03.027 · Cited by 102
Aripiprazole Added to Overweight and Obese Olanzapine-Treated Schizophrenia Patients
Henderson, D. C., Fan, X., Copeland, P. M., Sharma, B., Borba, C. P. C., Boxill, R., Freudenreich, O., Cather, C., Evins, A. E., & GOFF, D. C. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31819a8dbe · Cited by 102
Chan, J., & Sweeting, M. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106071334 · Cited by 101
Carrière, P., Bonhomme, D., & Lempérière, T. (2000) · European Psychiatry · doi:10.1016/s0924-9338(00)00401-6 · Cited by 100
First-Episode Schizophrenia: A Focus on Pharmacological Treatment and Safety Considerations
Kelly, D. L., Conley, R. R., & Carpenter, W. T. (2005) · Drugs · doi:10.2165/00003495-200565080-00006 · Cited by 98
Wassef, A. A., Dott, S. G., Harris, A., Brown, A., O'Boyle, M., Meyer, W. J., & Rose, R. M. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200006000-00011 · Cited by 98
Topiramate Add-On in Treatment-Resistant Schizophrenia
Tiihonen, J., Halonen, P. M., Wahlbeck, K., Repo‐Tiihonen, E., Hyvärinen, S., Eronen, M., Putkonen, H., Takala, P., Mehtonen, O. ‐., Puck, M., et al. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0808 · Cited by 98
Fell, M. J., McKinzie, D. L., Monn, J. A., & Svensson, K. A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.06.007 · Cited by 97
Češková, E., & Švestka, J. (1993) · Pharmacopsychiatry · doi:10.1055/s-2007-1014355 · Cited by 97
Peyrière, H., Roux, C., Ferard, C., Deleau, N., Kreft-Jaïs, C., Hillaire‐Buys, D., Boulenger, J., & Blayac, J. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1801 · Cited by 96
Clozapine Plus Lamotrigine in Treatment-Resistant Schizophrenia
Dursun, S. M., McIntosh, D., & Milliken, H. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.10.950 · Cited by 96
Antidepressants for the negative symptoms of schizophrenia
Rummel‐Kluge, C., Kissling, W., & Leucht, S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005581.pub2 · Cited by 95
HUTTUNEN, M. O., Piepponen, P. T., Rantanen, H., Larmo, I., Nyholm, R., & Raitasuo, V. (1995) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1995.tb09781.x · Cited by 95
A Comparative Effectiveness Study of Risperidone and Olanzapine in the Treatment of Schizophrenia
Ho, B., Miller, D. D., Nopoulos, P., & Andreasen, N. C. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n1003 · Cited by 95
Lecrubier, Y., Quintin, P., Bouhassira, M., Perrin, E., & Lancrenon, S. (2006) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2006.00887.x · Cited by 95
Pharmacotherapy of first-episode schizophrenia
Remington, G. J., Kapur, S., & Zipursky, R. B. (1998) · The British Journal of Psychiatry · doi:10.1192/s0007125000297687 · Cited by 94
Dorevitch, A., Katz, N., Zemishlany, Z., Aizenberg, D., & Weizman, A. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.1.142 · Cited by 94
Gäebel, W., Riesbeck, M., Wölwer, W., Klimke, A., Eickhoff, M., von Wilmsdorff, M., JOCKERS-SCHERÜBL, M. C., Kühn, K.-U., Lemke, M., Bechdolf, A., et al. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1116 · Cited by 93
Self-citationAfshar, H., Roohafza, H., Mousavi, S. G., Golchin, S., Toghianifar, N., Sadeghi, M., & Talaei, M. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108089816 · Cited by 92
Efficacy and Tolerability of Once-Daily Extended Release Quetiapine Fumarate in Acute Schizophrenia
Kahn, R. S., Schulz, S. C., Palazov, V., Reyes, E. B., Brecher, M., Svensson, O., Andersson, H., & Meulien, D. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0603 · Cited by 92
Praxisleitlinien in Psychiatrie und Psychotherapie
Menke, R., Wobrock, T., Weinmann, S., Janssen, B., Falkai, P., & Gäebel, W. (2006) · Zeitschrift für Psychiatrie Psychologie und Psychotherapie · doi:10.1024/1661-4747.54.1.3 · Cited by 92
Self-citationFabre, L. F., Arvanitis, L. A., Pultz, J. A., Jones, V. M., Malick, J. B., & Slotnick, V. B. (1995) · Clinical Therapeutics · doi:10.1016/0149-2918(95)80102-2 · Cited by 91
An example of European multicenter trials: multispectral analysis of clozapine.
Fischer-Cornelssen, K. A., & Uj, F. (1976) · PubMed · Cited by 91
Okuma, T., Yamashita, I., Takahashi, R., Itoh, H., Otsuki, S., Watanabe, S., Sarai, K., Hazama, H., & Inanaga, K. (1989) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1989.tb01334.x · Cited by 87
Amann, B. L., Pogarell, O. M., Mergl, R., et al. (2003) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.537 · Cited by 86
Emsley, R. A., Berwaerts, J., Eerdekens, M., Kramer, M. L., Lane, R., Lim, P., Hough, D., & Palumbo, J. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328314e1f3 · Cited by 86
Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia
McCue, R. E., Waheed, R., Urcuyo, L., Orendain, G. C. M., Joseph, M. D., Charles, R., & Hasan, S. M. (2006) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.105.019307 · Cited by 86
Canuso, C. M., Dirks, B., Carothers, J. L., Kosik‐Gonzalez, C., Bossie, C. A., Zhu, Y., Damaraju, C. V., Kalali, A. H., & Mahmoud, R. A. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.08040613 · Cited by 86
Antipsychotic combinations for schizophrenia
Ortiz‐Orendain, J., Castiello, S., Colunga‐Lozano, L. E., Hu, Y., Maayan, N., & Adams, C. E. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009005.pub2 · Cited by 85
Belgamwar, R. B., & Fenton, M. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003729.pub2 · Cited by 83
Carbamazepine for schizophrenia
Leucht, S., Helfer, B., Dold, M., Kissling, W., & McGrath, J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001258.pub3 · Cited by 82
Clozapine in China: a review and preview of US/PRC collaboration
Potter, W. Z., Ko, G. N., Zhang, L. D., et al. (1989) · Psychopharmacology · doi:10.1007/bf00442568 · Cited by 82
Broekema, W. J., de Groot, I. W., & van Harten, P. N. (2007) · Pharmacy World & Science · doi:10.1007/s11096-006-9063-1 · Cited by 81
Mortimer, A. M., Martin, S. D., Löo, H., & Peuskens, J. (2004) · International Clinical Psychopharmacology · doi:10.1097/00004850-200403000-00002 · Cited by 81
Heßlinger, B., Normann, C., Langosch, J. M., Klose, P., Berger, T., & Walden, J. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199908000-00005 · Cited by 80
Kane, J. M., Mackle, M., Snow‐Adami, L., Zhao, J., Szegedi, A., & Panagides, J. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06306 · Cited by 80
Wagner, M., Quednow, B. B., Westheide, J., Schlaepfer, T. E., Maier, W., & Kühn, K.-U. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300626 · Cited by 80
Delcker, A., Schoon, M., Oczkowski, B., & Gaertner, H. (1990) · Pharmacopsychiatry · doi:10.1055/s-2007-1014494 · Cited by 79
Impact of Clozapine on Negative Symptoms and on the Deficit Syndrome in Refractory Schizophrenia
Rosenheck, R., Dunn, L. A., Peszke, M. A., Cramer, J. A., Xu, W., Thomas, J. V., & Charney, D. S. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.1.88 · Cited by 79
Genç, Y., Taner, E., & Candansayar, S. (2007) · Advances in Therapy · doi:10.1007/bf02849987 · Cited by 78
Oosthuizen, P. P., Emsley, R. A., Maritz, J. S., Turner, J., & Keyter, N. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0913 · Cited by 78
Gureje, O., Miles, W., Keks, N. A., Grainger, D. L., Lambert, T., McGrath, J. J., Tran, P., Catts, S. V., Fraser, A., Hustig, H., et al. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00226-8 · Cited by 77
Using ECT in schizophrenia: A review from a clinical perspective
Zervas, I. M., Theleritis, C. G., & Soldatos, C. R. (2011) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.564653 · Cited by 77
Catatonia in Psychotic Patients: Clinical Features and Treatment Response
England, M. L., Öngür, D., Konopaske, G. T., & Karmacharya, R. (2011) · Journal of Neuropsychiatry · doi:10.1176/jnp.23.2.jnp223 · Cited by 76
Risperidone versus clozapine in treatment-resistant schizophrenia: A randomized pilot study
Wahlbeck, K., Cheine, M. V., Tuisku, K., Ahokas, A., Joffe, G., & Rimón, R. (2000) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(00)00118-4 · Cited by 76
Addington, D. E., Pantelis, C., Dineen, M., Benattia, I., & Romano, S. J. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1207 · Cited by 76
Möller, H., Riedel, M. J., Jäger, M., Wickelmaier, F., Maier, W., Kühn, K.-U., Buchkremer, G., Heuser, I., Klosterkötter, J., Gastpar, M., et al. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708008791 · Cited by 75
Self-citationChua, W. L. L., de Santiago, A. I., Kulkarni, J., & Mortimer, A. M. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004719.pub2 · Cited by 74
Heinrich, K., Klieser, E., Lehmann, E., Kinzler, E., & Hruschka, H. (1994) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(94)90029-9 · Cited by 74
Abbasi, S.-H., Behpournia, H., Ghoreshi, A., Salehi, B., Raznahan, M., Rezazadeh, S., Rezaei, F., & Akhondzadeh, S. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.11.008 · Cited by 74
Benzodiazepines for neuroleptic-induced acute akathisia
Lima, A. R., Soares‐Weiser, K., Bacaltchuk, J., & Barnes, T. R. E. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001950 · Cited by 73
Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study
Muscatello, M. R. A., Bruno, A., Pandolfo, G., Micò, U., Bellinghieri, P. M., Scimeca, G., Cacciola, M., Campolo, D., Settineri, S., & Zoccali, R. A. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110372548 · Cited by 73
Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse
Conley, R. R., Kelly, D. L., & Gale, E. (1998) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00062-0 · Cited by 73
Pharmacotherapy for treatment-resistant schizophrenia
Harrison, J., McIlwain, M., Wheeler, A., & Russell (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s12769 · Cited by 72
Oosthuizen, P. P., Emsley, R. A., Turner, H. J., & Keyter, N. (2004) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004262 · Cited by 72
Haloperidol dose for the acute phase of schizophrenia
Donnelly, L., Rathbone, J., & Adams, C. E. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001951.pub2 · Cited by 71
Olanzapine in Treatment-Refractory Schizophrenia
Martin, J., Gomez, J.-C., Bernardo, E. G., Cuesta, M. J., Álvarez, E., Manuel Gurpegui, A., & The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n1103 · Cited by 71
Self-citationRisperidone versus placebo for schizophrenia
Rattehalli, R. D., Zhao, S., Li, B. G., Jayaram, M., Xia, J., & Sampson, S. J. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006918.pub3 · Cited by 71
Gelenberg, A. J., & Doller, J. C. (1979) · PubMed · Cited by 70
Joffe, G., Terevnikov, V., Joffe, M., Stenberg, J., Burkin, M. M., & Tiihonen, J. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2008.12.002 · Cited by 69
Thomas, S. H. L., Drici, M. D., Hall, G. C., Crocq, M. A., Everitt, B., Lader, M. H., Jeunne, C. L., Naber, D., Priori, S., Sturkenboom, M., et al. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2010.01563.x · Cited by 67 · cited 3×
“However, this effect should also be taken into consideration for other frequently prescribed SGAs (Buchanan et al. 2010; Camm et al. 2012; Harrigan et al. 2004; Kreyenbuhl et al. 2010; Thomas et al. 2010).”
BackgroundSelf-citationPharmacological Management of First-Episode Schizophrenia and Related Nonaffective Psychoses
Bradford, D. W., Perkins, D. O., & Lieberman, J. A. (2003) · Drugs · doi:10.2165/00003495-200363210-00001 · Cited by 67
Self-citationCooper, S. J., Tweed, J. A., Raniwalla, J., Butler, A., & Welch, C. P. (2000) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2000.101003218.x · Cited by 67
Newcomer, J. W., Ratner, R. E., Eriksson, J. W., Emsley, R. A., Meulien, D., Miller, F., Leonova-Edlund, J., Leong, R. W., & Brecher, M. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04132 · Cited by 67
Epidemiology of neuroleptic malignant syndrome.
Adityanjee, Aderibigbe, Y. A., & Mathews, T. (1999) · PubMed · Cited by 66
Principles and Practice of Psychopharmacotherapy
van Kammen, D. P. (1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.8.1240 · Cited by 66
Sacchetti, E., Galluzzo, A., Valsecchi, P., Romeo, F., Gorini, B., & Warrington, L. E. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.02.017 · Cited by 66
Benzodiazepines alone or in combination with antipsychotic drugs for acute psychosis
Gillies, D. M., Beck, A., & McCloud, A. (2001) · doi:10.1002/14651858.cd003079 · Cited by 65
Polypharmacy With Second-Generation Antipsychotics: A Review of Evidence
Pandurangi, A., & Dalkiliç, A. (2008) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000341890.05383.45 · Cited by 65
Comparison of Quetiapine and Risperidone in the Treatment of Schizophrenia
Zhong, K., Sweitzer, D. E., Hamer, R. M., & Lieberman, J. A. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0712 · Cited by 65
Self-citationBerk, M., Gama, C. S., Sundram, S., Hustig, H., Koopowitz, L., D’Souza, R. F., Malloy, H., Rowland, C., Monkhouse, A., Monkhouse, A., et al. (2009) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1017 · Cited by 65
Cutler, A. J., Marcus, R. N., Hardy, S. A., O’Donnell, A., Carson, W. H., & McQuade, R. D. (2006) · CNS Spectrums · doi:10.1017/s1092852900014784 · Cited by 64
Olié, J., Spina, E., Murray, S., & Yang, R. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000182121.59296.70 · Cited by 64
Conley, R. R., Kelly, D. L., Nelson, M. W., Richardson, C. M., Feldman, S. M., Benham, R., Steiner, P., Yu, Y., Khan, I., McMullen, R., et al. (2005) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000172993.89879.0f · Cited by 64
Citrome, L. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02142.x · Cited by 64
Neurocognitive Effectiveness of Haloperidol, Risperidone, and Olanzapine in First-Episode Psychosis
Crespo‐Facorro, B., Rodríguez-Sánchez, J. M., Pérez‐Iglesias, R., Mata, I. F., Ayesa, R., Ramírez-Bonilla, M., Martínez‐García, O., & Vázquez‐Barquero, J. L. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04634 · Cited by 63
Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses
Jayakody, K., Gibson, R. C., Kumar, A., & Gunadasa, S. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000525.pub3 · Cited by 62
Hong, C.-J., Chen, J., Chiu, H.-J., & Sim, C. (1997) · International Clinical Psychopharmacology · doi:10.1097/00004850-199705000-00001 · Cited by 61
Álvarez, E., Ciudad, A., Olivares, J. M., Bousoño, M., & Gómez, J. C. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000222513.63767.de · Cited by 61
Leucht, S., Kissling, W., & McGrath, J. J. (2004) · PubMed · Cited by 60
Casey, D. E., Daniel, D. G., Tamminga, C. A., Kane, J. M., Tran-Johnson, T. K., Wozniak, P., Abi‐Saab, W., Baker, J. M., Redden, L., Greco, N., et al. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.209 · Cited by 60
Adjunctive Risperidone for Partially Responsive People with Schizophrenia Treated with Clozapine
Weiner, E., Conley, R. R., Ball, M. P., Feldman, S. M., Gold, J. M., Kelly, D. L., Wonodi, I., McMahon, R. P., & Buchanan, R. W. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.101 · Cited by 60
Commentary: Defining Treatment Refractoriness in Schizophrenia
Meltzer, H. Y. (1990) · Schizophrenia Bulletin · doi:10.1093/schbul/16.4.563 · Cited by 60
Premkumar, T. S., & Pick, J. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005962.pub2 · Cited by 59
Riedel, M. J., Müller, N., Strassnig, M., Spellmann, I., Engel, R. R., Musil, R., Dehning, S., Douhet, A., Schwarz, M., & Möller, H. ‐. (2005) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-005-0622-6 · Cited by 59
Self-citationOlanzapine in Refractory Schizophrenia After Failure of Typical or Atypical Antipsychotic Treatment
Lindenmayer, J., Czobor, P., Volavka, J., Lieberman, J. A., Citrome, L., Sheitman, B., Chakos, M., & McEvoy, J. P. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1011 · Cited by 59
Self-citationOlanzapine Treatment of Residual Positive and Negative Symptoms
Buchanan, R. W., Ball, M. P., Weiner, E., Kirkpatrick, B. W., Gold, J. M., McMahon, R. P., & Carpenter, W. T. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.1.124 · Cited by 59
Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation
Villari, V., Rocca, P., Fonzo, V., Montemagni, C., Pandullo, P., & Bogetto, F. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.09.007 · Cited by 58
Leucht, S. (2004) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004109 · Cited by 58
Switching From Clozapine to Olanzapine in Treatment-Refractory Schizophrenia
Henderson, D. C., Nasrallah, R. A., & GOFF, D. C. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n1105 · Cited by 57
Suzuki, T., Uchida, H., Takeuchi, H., Nakajima, S., Nomura, K., Tanabe, A., Yagi, G., Watanabe, K., & Kashima, H. (2009) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1073 · Cited by 57
Matheson, S. L., Green, M. J., Loo, C. K. A., & Carr, V. J. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.01.002 · Cited by 57
Volavka, J., Czobor, P., Derks, E. M., et al. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06529 · Cited by 56
Ishigooka, J., Inada, T., & Miura, S. (2001) · Psychiatry and Clinical Neurosciences · doi:10.1046/j.1440-1819.2001.00882.x · Cited by 56
Carbamazepine in violent non-epileptic schizophrenics.
Dj, L. (1984) · PubMed · Cited by 56
Fagerlund, B., Mackeprang, T., Gade, A., Hemmingsen, R., & Glenthoj, B. Y. (2004) · CNS Spectrums · doi:10.1017/s1092852900009354 · Cited by 55
Self-citationLewis, R. A., Bagnall, A., & Leitner, M. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001715.pub2 · Cited by 55
Cooper, S. J., Butler, A., Tweed, J. A., Welch, C. P., & Raniwalla, J. (2000) · Psychopharmacology · doi:10.1007/s002130000452 · Cited by 55
Freeman, H. L. (1997) · International Clinical Psychopharmacology · doi:10.1097/00004850-199705002-00004 · Cited by 55
Lithium for Schizophrenia Revisited
Leucht, S., Kissling, W., & McGrath, J. J. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0206 · Cited by 55
Martin, S. D., Löo, H., Peuskens, J., Thirumalai, S., Giudicelli, A., Fleurot, O., Rein, W., & for the SOLIANOL Study Group (2002) · Current Medical Research and Opinion · doi:10.1185/030079902125001128 · Cited by 54
Suzuki, T., Uchida, H., Watanabe, K., Nomura, K., Takeuchi, H., Tomita, M., Tsunoda, K., Nio, S., Den, R., Manki, H., et al. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0872-2 · Cited by 54
Dossenbach, M. R. K., Beuzen, J. N., Avnon, M., Belmaker, R. H., Elizur, A., Mark, M., Munitz, H., Schneidman, M., Shoshani, D., Kratky, P., et al. (2000) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)80082-x · Cited by 54
Cho, S., Yook, K., Kim, B., Choi, T. K., Lee, K. S., Kim, Y. W., Lee, J. E., Suh, S.-Y., Yook, K. H., & Lee, S. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.11.006 · Cited by 54
Cited by
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Galletly, C., Castle, D., Dark, F., Humberstone, V., Jablensky, A., Killackey, E., Kulkarni, J., McGorry, P., Nielssen, O., & Tran, N. (2016) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416641195 · Cited by 877
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & WFSBP Task force on Treatment Guidelines for Schizophrenia (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.739708 · Cited by 416
Self-citationThe impact of environmental factors in severe psychiatric disorders
Schmitt, A., Malchow, B., Hasan, A., & Falkai, P. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00019 · Cited by 322
Self-citation
Metadata
- Authors
- Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia
- Venue
- The World Journal of Biological Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2012-07
- Volume
- 13
- Issue
- 5
- Pages
- 318-378
- ISSN
- 1562-2975 (ISSN-L)
- 1814-1412
- OpenAlex
- W2157369969
- Cited by
- 637
- References
- 529
- FWCI
- 22.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.